Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT06427798RecruitingPhase 1/Phase 2
Radioactive drug for previously treated gut or adrenal tumors
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Bethesda, MarylandAges 18–120 - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Fort Smith, ArkansasAges 18 years+ - NCT07499362RecruitingPhase 2
Study of Pimicotinib for Japanese Patients with TGCT
This trial tests a new drug called pimicotinib for people in Japan with tenosynovial giant cell tumor (TGCT) that cannot be removed by surgery. It aims to see if the drug can help with pain and stiffness caused by the tumor.
ChūōkuAges 18 years+ - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07517107RecruitingPhase 2
Blood tests to guide gastric cancer treatment decisions
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
ShanghaiAges 18 years+ - NCT07517198RecruitingPhase 1
EXS74539 Study for Advanced Solid Tumors
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07530536Recruiting
Brain Stimulation to Help Movement After Brain Tumor Surgery
This trial tests whether repetitive transcranial magnetic stimulation (rTMS)—a non-invasive treatment that uses magnetic pulses to stimulate the brain—can help restore arm or leg movement in patients who have had weakness after brain tumor surgery. The goal is to see if this treatment is safe and effective for people recovering from surgery.
New York, New YorkAges 22–65 - NCT07532018RecruitingPhase 1
DXP-106 Treatment for Advanced Solid Tumors
This early-stage trial tests a new drug called DXP-106 in patients with advanced cancers (like lung, pancreatic, or breast cancer) that have stopped responding to standard treatments. The study aims to find the right dose and see if this drug can help slow or shrink these tumors.
Harbin, HeilongjiangAges 18–75 - NCT07536087Recruiting
Heat treatment for pancreatic cysts and neuroendocrine tumors
This trial tests a minimally invasive endoscopic procedure that uses heat to treat certain pancreatic cysts (fluid-filled sacs) and small neuroendocrine tumors (hormone-producing growths). It may be an option if surgery isn't possible or if you prefer to avoid it.
PragueAges 18 years+ - NCT07539441RecruitingPhase 1/Phase 2
Mirdametinib for brain and nervous system tumors
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
Basking Ridge, New JerseyAges 18 years+ - NCT07541430RecruitingPhase 2
Testing a New Drug for Desmoid Tumors
This study tests a new medication for adults with desmoid tumors (rare, slow-growing tumors that form in connective tissue). You may qualify if your tumor has grown recently, causes pain, or has come back after previous treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07552233Recruiting
NK Cell Therapy for Recurrent Brain Tumors
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07559864RecruitingPhase 2
Regorafenib plus Envafolimab for treatment-resistant gastrointestinal stromal tumors
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07560865RecruitingPhase 1
New Cell Therapy for Recurring Brain Cancer
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Minneapolis, MinnesotaAges 18–75 - NCT07563972RecruitingPhase 1
Immune Cell Injection for Advanced Solid Tumors
This trial tests a new treatment where immune cells (called macrophage exosomes) are injected directly into your tumor to help your body fight the cancer. It's designed for advanced cancers that have not responded to standard treatments.
Chengdu, SichuanAges 18–65 - NCT07567222RecruitingPhase 1
Vaccine therapy for advanced solid tumors
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
Chengdu, SichuanAges 18–75 - NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07593209Recruiting
New PET scan tracer for detecting cancer using EphA2
This study tests a new radioactive tracer (a type of dye) called 68Ga-DOTA-EphA2 that helps PET scanners find cancer cells. Researchers want to see if this tracer can better identify tumors in patients who may have cancer.
Shenyang, LiaoningAges 18–80 - NCT07594262Recruiting
Understanding Inflammation in Pituitary Tumors
This research study examines the inflammatory environment inside pituitary tumors (small glands in the brain) to better understand how they grow and respond to treatment. You would have surgery to remove the tumor as part of your normal care, and researchers would study the removed tissue to learn more.
Rome, LazioAges 18–100 - NCT07609277Recruiting
Blood test to track giant cell bone tumors
This study uses a simple blood test (TRACP-5b) to help diagnose and monitor giant cell tumors of the bone. Researchers want to see if this test can better track how the tumor responds to treatment or comes back over time.
BrnoAges 18 years+ - NCT07610798RecruitingPhase 1/Phase 2
Testing INV-8989 for Advanced Cancers With KRAS G12D Mutation
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
Guangzhou, GuangdongAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.